|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DCBLD1 |
Gene summary for DCBLD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DCBLD1 | Gene ID | 285761 |
| Gene name | discoidin, CUB and LCCL domain containing 1 | |
| Gene Alias | dJ94G16.1 | |
| Cytomap | 6q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q8N8Z6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 285761 | DCBLD1 | LZE24T | Human | Esophagus | ESCC | 8.77e-03 | 5.63e-02 | 0.0596 |
| 285761 | DCBLD1 | P2T-E | Human | Esophagus | ESCC | 1.96e-07 | 1.32e-01 | 0.1177 |
| 285761 | DCBLD1 | P4T-E | Human | Esophagus | ESCC | 8.21e-10 | 3.25e-01 | 0.1323 |
| 285761 | DCBLD1 | P5T-E | Human | Esophagus | ESCC | 1.40e-22 | 4.26e-01 | 0.1327 |
| 285761 | DCBLD1 | P8T-E | Human | Esophagus | ESCC | 2.04e-20 | 3.45e-01 | 0.0889 |
| 285761 | DCBLD1 | P9T-E | Human | Esophagus | ESCC | 1.13e-03 | 1.01e-01 | 0.1131 |
| 285761 | DCBLD1 | P11T-E | Human | Esophagus | ESCC | 4.28e-10 | 4.20e-01 | 0.1426 |
| 285761 | DCBLD1 | P12T-E | Human | Esophagus | ESCC | 7.61e-09 | 1.46e-01 | 0.1122 |
| 285761 | DCBLD1 | P15T-E | Human | Esophagus | ESCC | 2.59e-11 | 2.32e-01 | 0.1149 |
| 285761 | DCBLD1 | P16T-E | Human | Esophagus | ESCC | 9.03e-21 | 2.98e-01 | 0.1153 |
| 285761 | DCBLD1 | P19T-E | Human | Esophagus | ESCC | 6.44e-04 | 3.55e-01 | 0.1662 |
| 285761 | DCBLD1 | P21T-E | Human | Esophagus | ESCC | 2.62e-11 | 2.72e-01 | 0.1617 |
| 285761 | DCBLD1 | P23T-E | Human | Esophagus | ESCC | 5.40e-16 | 3.68e-01 | 0.108 |
| 285761 | DCBLD1 | P24T-E | Human | Esophagus | ESCC | 4.84e-29 | 7.86e-01 | 0.1287 |
| 285761 | DCBLD1 | P26T-E | Human | Esophagus | ESCC | 1.24e-06 | 1.86e-01 | 0.1276 |
| 285761 | DCBLD1 | P27T-E | Human | Esophagus | ESCC | 4.96e-03 | 7.10e-02 | 0.1055 |
| 285761 | DCBLD1 | P28T-E | Human | Esophagus | ESCC | 9.83e-13 | 2.58e-01 | 0.1149 |
| 285761 | DCBLD1 | P31T-E | Human | Esophagus | ESCC | 2.53e-37 | 8.00e-01 | 0.1251 |
| 285761 | DCBLD1 | P32T-E | Human | Esophagus | ESCC | 9.89e-18 | 4.56e-01 | 0.1666 |
| 285761 | DCBLD1 | P36T-E | Human | Esophagus | ESCC | 1.29e-34 | 1.74e+00 | 0.1187 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DCBLD1 | SNV | Missense_Mutation | c.328N>A | p.Pro110Thr | p.P110T | Q8N8Z6 | protein_coding | tolerated(0.15) | possibly_damaging(0.805) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DCBLD1 | SNV | Missense_Mutation | novel | c.755N>G | p.Ser252Cys | p.S252C | Q8N8Z6 | protein_coding | deleterious(0) | possibly_damaging(0.879) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DCBLD1 | SNV | Missense_Mutation | rs767838532 | c.557N>T | p.Ser186Phe | p.S186F | Q8N8Z6 | protein_coding | tolerated(0.13) | benign(0.085) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| DCBLD1 | SNV | Missense_Mutation | c.1219G>A | p.Val407Met | p.V407M | Q8N8Z6 | protein_coding | tolerated(0.1) | benign(0.39) | TCGA-E9-A1R0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| DCBLD1 | SNV | Missense_Mutation | novel | c.697N>A | p.Ala233Thr | p.A233T | Q8N8Z6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-S3-AA11-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | CR |
| DCBLD1 | SNV | Missense_Mutation | novel | c.680G>A | p.Arg227Gln | p.R227Q | Q8N8Z6 | protein_coding | tolerated(0.13) | probably_damaging(0.95) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DCBLD1 | SNV | Missense_Mutation | novel | c.932G>A | p.Arg311Gln | p.R311Q | Q8N8Z6 | protein_coding | tolerated(0.33) | benign(0.024) | TCGA-VS-A9UJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| DCBLD1 | SNV | Missense_Mutation | c.451G>A | p.Asp151Asn | p.D151N | Q8N8Z6 | protein_coding | tolerated(0.17) | benign(0.334) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| DCBLD1 | SNV | Missense_Mutation | c.397N>A | p.Glu133Lys | p.E133K | Q8N8Z6 | protein_coding | tolerated(0.33) | benign(0.007) | TCGA-F4-6704-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
| DCBLD1 | SNV | Missense_Mutation | novel | c.697N>A | p.Ala233Thr | p.A233T | Q8N8Z6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 285761 | DCBLD1 | NA | cisplatin | CISPLATIN | 23478653 | |
| 285761 | DCBLD1 | NA | irinotecan | IRINOTECAN | 23478653 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |